This product's status changed to Approval withdrawn on 2025.03.28. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Summary
- Main use
- Improvement of nutritional status in children (including neonates and premature infants) when oral or enteral intake is difficult
- Who receives it
- Adults · Children
- Adult administration
- Consider the additional nutrition supplied apart from this drug when determining the initiation, duration, and dose (daily dose and infusion rate) of this drug as parenteral nutrition therapy. ○Dose Based on the patient's body weight, age, clinical condition, nitrogen requirements, and capacity for amino acid metabolism: -Amino acids: 1.5~3.5 g/kg body weight per day -Nitrogen: 0.23~0.53 g/kg body weight per day -This drug: 15~35 mL/kg body weight per day ○Administration -Infusion rate: Do not exceed 0.05 mL/kg/min. The flow rate should be adjusted according to the daily protein dose, daily infusion volume, and infusion duration, and should be gradually increased during the first hour after starting administration. ○Route of administration -When administered alone: Via a central vein -When administered concomitantly or mixed with other drugs: Via a peripheral or central vein, according to the final osmolarity of the infusion solution - Hypertonic parenteral nutrition solutions with an osmolarity exceeding 900 mOsm/L must be administered through a central venous catheter with its tip positioned in a large central vein. - When deemed appropriate by a healthcare professional, parenteral nutrition solutions with an osmolarity of 900 mOsm/L or less may be administered via a peripheral vein to patients of any age.
- Child administration
- -Neonates and infants: Continuous infusion over 24 hours -Children: Continuous infusion over 24 hours or cyclical infusion over 8~12 hours per day This drug is usually administered concomitantly or as a mixture with an energy source appropriate to the needs of the child.
Ingredients
- L-Valine0.76g / 100mL
- L-Leucine1000g / 100mL
- L-Isoleucine0.67g / 100mL
- Taurine0.06g / 100mL
- L-Ornithine Hydrochloride0.318g / 100mL
- L-Tyrosine0.045g / 100mL
- L-Serine0.4g / 100mL
- L-Proline0.3g / 100mL
- Glycine0.4g / 100mL
- L-Glutamic Acid1000g / 100mL
- L-Cysteine0.189g / 100mL
- L-Aspartic Acid0.6g / 100mL
- L-Alanine0.8g / 100mL
- L-Histidine0.38g / 100mL
- L-Arginine0.84g / 100mL
- L-Tryptophan0.2g / 100mL
- L-Threonine0.37g / 100mL
- L-Phenylalanine0.42g / 100mL
- L-Methionine0.24g / 100mL
- L-Lysine Solution 50%2200g / 100mL
- Importer
- VANTIVE KOREA INCORPORATED
Efficacy & effects
Improvement of nutritional status in children (including neonates and premature infants) when oral or enteral intake is difficult
View approved original textHide original text
This medication is used to supply nutrition through non-oral methods in cases where oral or enteral nutrition is not possible or insufficient, especially in infants, children, and newborns of normal weight or low birth weight as well as preterm infants.
How it is given
Adult administration
Consider the additional nutrition supplied apart from this drug when determining the initiation, duration, and dose (daily dose and infusion rate) of this drug as parenteral nutrition therapy. ○Dose Based on the patient's body weight, age, clinical condition, nitrogen requirements, and capacity for amino acid metabolism: -Amino acids: 1.5~3.5 g/kg body weight per day -Nitrogen: 0.23~0.53 g/kg body weight per day -This drug: 15~35 mL/kg body weight per day ○Administration -Infusion rate: Do not exceed 0.05 mL/kg/min. The flow rate should be adjusted according to the daily protein dose, daily infusion volume, and infusion duration, and should be gradually increased during the first hour after starting administration. ○Route of administration -When administered alone: Via a central vein -When administered concomitantly or mixed with other drugs: Via a peripheral or central vein, according to the final osmolarity of the infusion solution - Hypertonic parenteral nutrition solutions with an osmolarity exceeding 900 mOsm/L must be administered through a central venous catheter with its tip positioned in a large central vein. - When deemed appropriate by a healthcare professional, parenteral nutrition solutions with an osmolarity of 900 mOsm/L or less may be administered via a peripheral vein to patients of any age.
Child administration
-Neonates and infants: Continuous infusion over 24 hours -Children: Continuous infusion over 24 hours or cyclical infusion over 8~12 hours per day This drug is usually administered concomitantly or as a mixture with an energy source appropriate to the needs of the child.
Precautions
This drug should be used with caution in patients with severely impaired heart, respiratory, or kidney function. In particular, children with reduced kidney function should control nitrogen intake. Patients with allergies to any of the amino acids, excipients, or container materials in this drug should not use it. During use, there may be hypersensitivity reactions such as facial or eyelid swelling and rashes, so caution is needed. Symptoms of increased ammonia levels in the blood have also been reported. During infusion, severe allergic reactions such as anaphylaxis may occur, so if such symptoms appear, infusion should be discontinued immediately. This drug poses a risk of precipitate formation in pulmonary vessels, so if pain is felt in the lungs, administration should be stopped immediately, and examinations should be performed. Regular checks should also be made for precipitates in the infusion set or catheter. Intravenous administration poses an infection risk, so special care should be taken for catheter management and aseptic handling. When resuming nutritional supply abruptly, symptoms such as electrolyte imbalance, fluid overload, and thiamine deficiency may occur, so administration should be gradual and closely monitored. Infusion of hypertonic solutions into peripheral veins can cause venous irritation or thrombosis, so caution is required. During administration, fluid and electrolyte balance, blood sugar, liver, and kidney function should be regularly monitored and observed carefully. Patients with impaired liver function may develop liver-related complications, so liver function values should be monitored frequently, and consultation with a specialist should be performed as needed. Patients with reduced kidney function may have decreased nitrogen excretion capabilities, so dose adjustment and fluid status management should be performed carefully. During administration, exposure to light should be avoided to prevent drug degradation, and extra caution should be taken with newborns and children under 2 years old. Thrombophlebitis, necrosis, or blistering may occur at the injection site, so the patient's condition should be monitored closely. Overdosing or infusing too rapidly can lead to serious side effects such as volume overload, electrolyte abnormality, acidosis, and azotemia, necessitating immediate discontinuation and appropriate treatment. Caution should be taken not to excessively add calcium and phosphate, as this may lead to precipitate formation. Before administration, confirm that the solution is clear and the container is not damaged, and any remainder after opening should be discarded immediately. Maintain a sterile state while mixing drugs and ensure no foreign substances are administered using infusion sets and filters. The safety of this drug for pregnant or breastfeeding women has not been established, so the benefits and risks should be carefully evaluated before use. The effect on driving or operating machinery is not known.
Side effects
- facial swelling
- eyelid swelling
- rash
- azotemia
- hyperammonemia
- anaphylaxis
- anaphylactic reaction
- fever
- chills
- hypotension
Show 31 moreCollapse
- hypertension
- arthralgia
- myalgia
- urticaria
- pruritus
- erythema
- headache
- liver failure
- cirrhosis
- liver fibrosis
- cholestasis
- fatty liver
- elevated blood bilirubin
- increased liver enzymes
- cholecystitis
- cholelithiasis
- metabolic acidosis
- pulmonary vascular deposits
- necrosis at injection site
- blisters
- edema
- scars
- skin discoloration
- thrombophlebitis at injection site
- venous irritation
- phlebitis at injection site
- pain
- erythema
- warmth
- edema
- sclerosis
Not everyone experiences these, and they can vary from person to person.
Storage
This drug should be stored in a sealed container to prevent exposure to air or moisture, ideally at a temperature between 1 and 25 degrees Celsius. This storage helps maintain the drug's effectiveness and prevents deterioration.
Appearance and packaging
Appearance
A colorless to pale yellow transparent solution in a colorless transparent glass vial, with a rubber stopper for infusion.
Package unit
100, 250ml/vial
Questions about this medicine
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.